The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening
Open accessAbstract
BACKGROUND: Primary cervical screening with both human papillomavirus (HPV) DNA testing and cytological examination of cervical cells with a Pap test (cytology) has been evaluated in randomized clinical trials. Because the vast majority of women with positive cytology are also HPV DNA positive, screening strategies that use HPV DNA testing as the primary screening test may be more effective. METHODS: We used the database from the intervention arm (n = 6,257 women) of a population-based randomized trial of double screening with cytology and HPV DNA testing to evaluate the efficacy of 11 possible cervical screening strategies that are based on HPV DNA testing alone, cytology alone, and HPV DNA testing combined with cytology among women aged 32-38 years. The main outcome measures were sensitivity for detection of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) within 6 months of enrollment or at colposcopy for women with a persistent type-specific HPV infection and the number of screening tests and positive predictive value (PPV) for each screening strategy. All statistical tests were two-sided. RESULTS: Compared with screening by cytology alone, double testing with cytology and for type-specific HPV persistence resulted in a 35% (95% confidence interval [CI] = 15% to 60%) increase in sensitivity to detect CIN3+, without a statistically significant reduction in the PPV (relative PPV = 0.76, 95% CI = 0.52 to 1.10), but with more than twice as many screening tests needed. Several strategies that incorporated screening for high-risk HPV subtypes were explored, but they resulted in reduced PPV compared with cytology. Compared with cytology, primary screening with HPV DNA testing followed by cytological triage and repeat HPV DNA testing of HPV DNA-positive women with normal cytology increased the CIN3+ sensitivity by 30% (95% CI = 9% to 54%), maintained a high PPV (relative PPV = 0.87, 95% CI = 0.60 to 1.26), and resulted in a mere 12% increase in the number of screening tests (from 6,257 to 7,019 tests). CONCLUSIONS: Primary HPV DNA-based screening with cytology triage and repeat HPV DNA testing of cytology-negative women appears to be the most feasible cervical screening strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Kirkwood, B. R., & Sterne, J. A. C. (2014) · Bristol Research (University of Bristol) · Cited by 2,820
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Mayrand, M.-H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlée, F., & Franco, E. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071430 · Cited by 1,100
Nanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Khan, M. J., Castle, P. E., Lorincz, A. T., Wacholder, S., Sherman, M., Scott, D. R., Rush, B. B., Glass, A. G., & Schiffman, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji187 · Cited by 1,053
Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
Naucler, P., Ryd, W., Törnberg, S., Strand, A., Wadell, G., Elfgren, K., Rådberg, T., Strander, B., Johansson, B., Forslund, O., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073204 · Cited by 797
Self-citationDiagnostic Cytology and Its Histopathologic Bases.
(1968) · Annals of Internal Medicine · doi:10.7326/0003-4819-69-6-1341_1 · Cited by 775
Bulkmans, N., Berkhof, J., Rozendaal, L., van Kemenade, F., Boeke, A., Bulk, S., Voorhorst, F., Verheijen, R., van Groningen, K., Boon, M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 637
Jacobs, M. V., Snijders, P. J., van den Brule, A. J., Helmerhorst, T. J., Meijer, C. J., & Walboomers, J. M. (1997) · Journal of Clinical Microbiology · doi:10.1128/jcm.35.3.791-795.1997 · Cited by 568
Cited by
Screening for cervical cancer: U.S. preventive services Task force recommendation statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-12-201206190-00424 · Cited by 1,049
Guan, P., Howell‐Jones, R., Li, N., Bruni, L., de Sanjosé, S., Franceschi, S., & Clifford, G. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27485 · Cited by 927
Evidence Regarding Human Papillomavirus Testing in Secondary Prevention of Cervical Cancer
Arbyn, M., Ronco, G., Anttila, A., Meijer, C. J. L. M., Poljak, M., Ogilvie, G., Koliopoulos, G., Naucler, P., Sankaranarayanan, R., & Peto, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.095 · Cited by 897
Self-citationHuman Papillomavirus Testing in the Prevention of Cervical Cancer
Schiffman, M., Wentzensen, N., Wacholder, S., Kinney, W., Gage, J. C., & Castle, P. E. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq562 · Cited by 759
Cytology versus HPV testing for cervical cancer screening in the general population
Koliopoulos, G., Nyaga, V. N., Santesso, N., Bryant, A., Martin-Hirsch, P. P., Mustafa, R. A., Schünemann, H., Paraskevaidis, E., & Arbyn, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008587.pub2 · Cited by 494
Metadata
- Authors
- Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., Radberg, T., Strander, B., Forslund, O., Hansson, B.-G., Hagmar, B., Johansson, B., Rylander, E., & Dillner, J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-13
- Volume
- 101
- Issue
- 2
- Pages
- 88-99
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2156680734
- Cited by
- 287
- References
- 35
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. https://app.cochat.ai/papers/10.1093/jnci/djn444
- The paper
- Naucler, P., Ryd, W., Tornberg, S., Strand, A., Wadell, G., Elfgren, K., Radberg, T., Strander, B., Forslund, O., Hansson, B.-G., Hagmar, B., Johansson, B., Rylander, E., & Dillner, J. (2009). Efficacy of HPV DNA Testing With Cytology Triage and/or Repeat HPV DNA Testing in Primary Cervical Cancer Screening. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djn444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
